Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Cannot exceed 8...

    Cannot exceed 8 percent trade margin on Stents: NPPA

    Written by Ruby Khatun Khatun Published On 2017-08-04T18:00:59+05:30  |  Updated On 22 Dec 2022 3:14 PM IST
    Cannot exceed 8 percent trade margin on Stents: NPPA

    New Delhi: NPPA has taken a step ahead to prevent distributors from grabbing higher profits and manipulating trade margins on coronary stents than the allowed margins by the government.


    Through a recent notification, Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals and National Pharmaceutical pricing Authority (NPPA) has clarified that any person who imports stents directly without having registration certificate from the central drug regulator with an undertaking from companies that have a registration certificate will also be considered as a 'distributor'.


    In the notification, NPPA has further stressed that only 8% of trade margin can be added in excess on the cost of the stent.


    Taking this step, NPPA has tried to stop distributors from importing stents on behalf of foreign companies and adding high margins while selling the devices across the value chain. It has also initiated an attack against hospitals which are overcharging on stents . For the same, NPPA through a demand notice has fined Rs. 1.26 lakh to Metro Heart Institute, Faridabad asking them to pay fine to the department of pharmaceuticals for allegedly overcharging patients for stents.


    Read also: New Delhi: Metro Hospital fined Rs 1.26 Lakh for stent overcharging

    Find the attachment for the same


    http://www.nppaindia.nic.in/order/addendum08030217.pdf

    Coronary StentsDemand NoticeDepartment of PharmaceuticalsDistributorsfineGovernment of IndiaMetro Heart InstituteMinistry of Chemicals and FertilizersNational Pharmaceutical Pricing AuthorityNPPAprofitsRegistration CertificateStentstrade margin

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok